Form 4: MoonLake CSO Kristian Reich Converts Shares

MoonLake Immunotherapeutics' Chief Scientific Officer, Kristian Reich, converted MoonLake AG common shares into Class A ordinary shares of the issuer, increasing his direct beneficial ownership.

Summary

• Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, exchanged 1,456 common shares of MoonLake Immunotherapeutics AG for 48,978 Class A ordinary shares of MoonLake Immunotherapeutics.
• Concurrently, 48,978 Class C ordinary shares of the Issuer were automatically cancelled for no consideration as part of the exchange.
• The exchange rate for MoonLake AG common shares into Class A ordinary shares is 1 common share for 33.638698 Class A ordinary shares, rounded to the nearest whole share.
• Following this transaction, direct beneficial ownership includes 202,908 Class A ordinary shares and 35,389 Class C ordinary shares.
• Indirect beneficial ownership of 2,974,551 Class A ordinary shares is held through JeruCON Beratungsgesellschaft mbH, for which Dr. Reich may be deemed an indirect beneficial owner.
• 10,000 common shares of MoonLake AG, referred to as "second leaver shares," are subject to a reverse vesting condition, with 25% vested on January 18, 2023, and the remaining 75% vesting at a rate of 2.08% on the 18th of each month, achieving full vesting by January 18, 2026.

Sentiment

Score: 5

Explanation: The filing is a routine insider transaction report detailing a share conversion, which is a neutral event in terms of company performance or strategic direction. It does not inherently convey positive or negative sentiment about the company's prospects.

Positives

• Increased direct beneficial ownership of 48,978 Class A ordinary shares of MoonLake Immunotherapeutics by the Chief Scientific Officer, aligning his interests further with shareholders.

Negatives

• No direct negative financial impact identified as the cancellation of Class C ordinary shares was for no consideration and part of a conversion mechanism.

Risks

• 10,000 common shares of MoonLake AG held by the reporting person are subject to reverse vesting conditions, with full vesting by January 18, 2026.
• If the holder's employment is terminated before the end of the second vesting period (January 18, 2026) for any reason other than cause, MoonLake AG or a designated third party has an option to purchase all or a pro rata portion of the unvested second leaver shares at a nominal value of CHF 0.10 per share.
• If employment is terminated for cause, MoonLake AG or a designated third party has an option to purchase all or a pro rata portion of the second leaver shares at a nominal value of CHF 0.10 per share.

Future Outlook

The filing indicates that 10,000 'second leaver shares' of MoonLake AG held by the reporting person are subject to a reverse vesting schedule, with full vesting anticipated by January 18, 2026. This outlines a future milestone for the reporting person's equity holdings.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a share conversion, which is common for executives in companies with complex equity structures, particularly those that may have undergone a corporate restructuring or a public listing involving different classes of shares or subsidiary entities. It does not directly reflect broader industry trends but is a standard compliance event for publicly traded companies.

Related Party Transactions

• Dr. Reich may be deemed an indirect beneficial owner of 2,974,551 Class A ordinary shares owned by JeruCON Beratungsgesellschaft mbH.

Stakeholder Impact

• Shareholders: The transaction increases the Chief Scientific Officer's direct ownership of Class A ordinary shares, potentially aligning management interests more closely with public shareholders. The conversion itself is a technical adjustment to equity structure rather than a change in overall economic interest.
• Employees (specifically Dr. Reich): The vesting schedule for 'second leaver shares' outlines future equity milestones and potential implications upon employment termination.

Next Steps

• Continued vesting of the remaining 'second leaver shares' of MoonLake AG until full vesting on January 18, 2026.

Key Dates

Keywords

MLTX, MoonLake Immunotherapeutics, Kristian Reich, Chief Scientific Officer, Form 4, Beneficial Ownership, Share Conversion, Insider Transaction, Equity Exchange, Vesting Conditions